These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24740170)

  • 1. Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.
    Yang LP; McKeage K
    Drugs Aging; 2014 May; 31(5):395-404. PubMed ID: 24740170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
    Kymes SM; Oden NL; VanVeldhuisen PC; Scott IU; Ip MS; Blodi BA; King J;
    JAMA Ophthalmol; 2023 Jun; 141(6):554-561. PubMed ID: 37166820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice.
    Kim ID; Cave JW; Cho S
    Stroke; 2021 Aug; 52(8):2637-2648. PubMed ID: 34192895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Aflibercept Treatment for Macular Disease.
    Anguita R; Tasiopoulou A; Shahid S; Roth J; Sim SY; Patel PJ
    Ophthalmol Ther; 2021 Sep; 10(3):413-428. PubMed ID: 34120317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of
    Ragkousis A; Kazantzis D; Georgalas I; Theodossiadis P; Kroupis C; Chatziralli I
    Semin Ophthalmol; 2024 Apr; 39(3):201-208. PubMed ID: 37997789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presumed Melanocytoma-Associated Choroidal Neovascular Membrane with Hemorrhage Successfully Treated with Intravitreal Aflibercept Injections.
    Yu AS; Sugarman JA; Weiss SJ
    Case Rep Ophthalmol; 2023; 14(1):421-425. PubMed ID: 37901621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation.
    Klaas JE; Bui V; Maierhofer N; Schworm B; Maier M; Priglinger SG; Siedlecki J
    Front Med (Lausanne); 2023; 10():1295633. PubMed ID: 37954554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model.
    Lange C; Tetzner R; Strunz T; Rittenhouse KD
    Transl Vis Sci Technol; 2023 Oct; 12(10):5. PubMed ID: 37801302
    [No Abstract]   [Full Text] [Related]  

  • 11. Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea
    Lee H; Huh J; Kim D; Lee S; Lee J; Lee J; Kim BC; Song J
    Ophthalmol Ther; 2024 Aug; 13(8):2209-2225. PubMed ID: 38878130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infographic: Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE).
    Wijesingha N; Sivaprasad S
    Eye (Lond); 2024 Aug; 38(Suppl 2):51-52. PubMed ID: 38123671
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
    Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
    Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
    ; Wells JA; Glassman AR; Ayala AR; Jampol LM; Aiello LP; Antoszyk AN; Arnold-Bush B; Baker CW; Bressler NM; Browning DJ; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW
    N Engl J Med; 2015 Mar; 372(13):1193-203. PubMed ID: 25692915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2015 Mar; 159(3):607-8. PubMed ID: 25681022
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.